Jubilant Biosys Announces Successful Achievement of an Early Milestone Related to One of Their Collaborative Discovery Programs

Food and Healthcare Press Releases Wednesday November 29, 2017 17:59
BENGALURU--29 Nov--PRNewswire/InfoQuest

Jubilant Biosys Ltd. , a Bengaluru-based subsidiary of Jubilant Life Sciences Ltd., announced today that they successfully achieved an early-stage milestone related to a collaborative program with Sanofi in Frankfurt, Germany focused on metabolic disorders. The milestone reflects the successful transition of a collaborative program to the next phase in the discovery and development process.

(Logo: http://photos.prnewswire.com/prnh/20160107/783587 )

This alliance is part of a portfolio of programs, which began in 2016, focused on the   discovery and development of small molecule inhibitors for multiple targets designed to address the unmet medical needs in diabetes and obesity. Jubilant Biosys confirmed receiving payment for the first milestone achievement for this collaboration. Jubilant Biosys will continue to apply its effective integrated drug discovery platform to generate novel molecules that can demonstrate clinical proof-of-mechanism.

"Jubilant Biosys has invested in its metabolic disease platform to enable the discovery and development of small molecule therapeutics. Since inception of this collaboration, the teams at Jubilant Biosys and Sanofi have worked closely on several first-in-class metabolic disease programs. We look forward to advancing these programs further through the discovery and development process to deliver important new therapeutics to treat diabetes," said Mr. Steven Hutchins, Jubilant Biosys, President, Drug Discovery Solutions.

Dr. Philip Just Larsen, Global Head of Diabetes Research & Chief Scientific Officer, Sanofi, Germany, said: "Sanofi works on continuously innovating to deliver value for people living with metabolic disorders. This productive collaboration with Jubilant Biosys further illustrates our commitment to discover and develop new therapies to support patients with diabetes or its complications."

About Jubilant Biosys Limited

Jubilant Biosys a subsidiary of Jubilant Life sciences Ltd, an integrated global pharmaceutical and life sciences company, has presence in Bengaluru and Noida in India. Jubilant Biosys has demonstrated expertise in multiple therapeutic areas including but not limited to Oncology, Metabolic Disorders, Pain & Inflammation and CNS. The business model includes drug discovery services, proprietary in-house innovation and strategic investments as the core components which are available for collaborative research, partnership and out-licensing.

For more info: http://www.jubilantbiosys.com ; http://www.jubl.com
For Business Development:
Dr. Rajiv Tyagi
Tel: +91-80-66628400
Email: Rajiv_Tyagi@jubilantbiosys.com
Source: Jubilant Biosys

Latest Press Release

Singapore National Eye Centre, Singapore Eye Research Institute And Johnson Johnson Vision Set Sights On Halting Global Myopia Epidemic

New US$26.35 Million Collaboration Seeks Prevention and Treatment Solutions to Address Rising Burden of Condition The Singapore National Eye Centre (SNEC), the Singapore Eye Research Institute (SERI) and Johnson & Johnson Vision today announced a...

TIENS Group Launches Global Expansion Into New Retail

Leading healthcare company, TIENS Group, has announced their global expansion into the new retail market with the opening of a new flagship TIENS Experience Store in China. Located in the TIENS International Health Industrial Park, the new store features...

Medicines We Can Trust Campaign Rallies Mekong Governments and Leaders to Improve Access to Quality Medicines

Cambodian Prime Minister Hun Sen and other leaders from the Greater Mekong Subregion joined hands as part of a global campaign to improve access to quality medicines. The announcement was made during the Phnom Penh Regional Conference on the fight...

SI Group Announces New Executive Leadership

SI Group, a leading global developer and manufacturer of performance additives, process solutions, pharmaceuticals and chemical intermediates, announced today the company's new executive leadership team. These changes follow the October 15, 2018...

Grunenthal Acquires Global Rights for Qutenza(R)

Grunenthal, the science-focused pharmaceutical company based in Germany, announced today that it has acquired additional global commercial rights for the dermal pain patch Qutenza(R) (8% capsaicin) from Acorda Therapeutics, Inc (USA). Grunenthal is now...

Related Topics